Endologix (ELGX +2.3%) presents data from its clinical trial of a totally percutaneous approach to endovascular abdominal aortic aneurysm repair, says the study demonstrated that the approach is non-inferior to surgical endovascular repair, and also has significantly reduced procedure times and time to hemostasis. The study also demonstrated positive trends toward lower blood loss, less need for pain medication, and shorter lengths of stay.
From other sites
at CNBC.com (Feb 28, 2014)
at CNBC.com (Dec 5, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs